Livengood C H, Thomason J L, Hill G B
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina.
Obstet Gynecol. 1990 Jul;76(1):118-23.
We tested topical intravaginal clindamycin phosphate at concentrations of 0.1, 1.0, and 2.0% in the treatment of 62 women with symptomatic bacterial vaginosis in a prospective, randomized, double-blind, placebo-controlled trial, and offered open-label treatment with 1.0% clindamycin to patients with persistent disease after blinded treatment. Blinded intravaginal clindamycin phosphate treatment cured bacterial vaginosis in 93.5% (43 of 46) of patients 4-7 days after therapy, compared with 25.0% (four of 16) of patients receiving placebo (P less than .001). One month later, 89.7% (35 of 39) of those who initially responded to clindamycin treatment showed persistent cure. There were no significant side effects.
在一项前瞻性、随机、双盲、安慰剂对照试验中，我们测试了浓度为0.1%、1.0%和2.0%的阴道局部用磷酸克林霉素治疗62例有症状细菌性阴道病的女性患者，并在盲法治疗后为持续患病的患者提供1.0%克林霉素的开放标签治疗。治疗4至7天后，盲法阴道用磷酸克林霉素治疗使93.5%（46例中的43例）患者的细菌性阴道病得到治愈，而接受安慰剂治疗的患者中这一比例为25.0%（16例中的4例）（P<0.001）。一个月后，最初对克林霉素治疗有反应的患者中有89.7%（39例中的35例）持续治愈。未出现明显副作用。
